Release Date: December 16, 2025
Expiration Date: January 28, 2026
Activity Overview
Chronic myeloid leukemia (CML) remains a complex hematologic malignancy despite dramatic improvements in outcomes with tyrosine kinase inhibitors (TKIs). As 6 TKIs are now FDA approved for CML, each with unique efficacy and safety profiles, clinicians face challenges in sequencing these agents, managing resistance, and addressing treatment-related adverse events. Continuous education is needed to help clinicians integrate new evidence, optimize therapeutic decisions, and enhance multidisciplinary collaboration to improve patient outcomes.
This Medical Crossfire® symposium features concise didactic updates and an expert panel debate. Through real-world case discussions, polling, and Q&A, participants will explore the evolving role of TKIs, resistance mechanisms, and emerging therapies.
This educational activity is an archive of the live presentation held on December 15, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward hematologists/oncologists, nurses, nurse practitioners, physician assistants, pharmacists, and any other health care providers involved in the diagnosis and treatment of CML.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Analyze the latest clinical data on first-line therapies and apply emerging evidence to optimize initial treatment selection in CML
- Evaluate strategies for treatment sequencing across multiple lines of therapy in CML
- Implement effective approaches to manage adverse events and enhance patient safety
- Develop individualized care plans that improve outcomes and support long-term disease management
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here